Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nerve block could replace sedation for shoulder dislocation

NCT ID NCT06034873

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an ultrasound-guided nerve block (PENG block) works better than IV sedation for reducing pain when a dislocated shoulder is put back in place. 42 adults participated, and researchers measured pain levels, reduction time, and hospital stay. The goal is to find a safer option for patients who cannot have sedation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine
What this could lead to
If successful, this approach could offer a safer, faster way to manage pain during shoulder dislocation reduction, especially for patients who cannot tolerate sedation.
What could go wrong
This is a small, early-phase trial with only 42 participants. The results may not apply to all patients, and nerve blocks carry risks like allergic reaction or incomplete pain relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

42 people

The number who actually took part.

Started

Nov 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (ASA )classes I and II * patients of either sex, above the age of 18 * patients will undergo dislocated shoulder Exclusion Criteria: * the patient's refusal to participate * coagulation disorders * allergy to local anesthetic * history of daily opioid intake * patients with cognitive impairments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Perioperative pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Banha faculity of medicine

    Banhā, Elqalyoubea, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.